Citadel Aurobindo Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 2.00 Cr
- Company Age 22 Year, 11 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 40.00 Cr
- Revenue Growth -44.42%
- Profit Growth -9583.74%
- Ebitda -432.91%
- Net Worth -0.01%
- Total Assets -76.73%
About Citadel Aurobindo Biotech
Citadel Aurobindo Biotech Limited (CABL) is a Public Limited Indian Non-Government Company incorporated in India on 22 March 2002 and has a history of 22 years and 11 months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company has closed loans amounting to ₹40.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mruthyunjaya Kapuluru, Rajiv Krishnamurthy, and Sardar Singh serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231TN2002PLC048652
- Company No.
048652
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
22 Mar 2002
- Date of AGM
05 Sep 2020
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Citadel Aurobindo Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mruthyunjaya Kapuluru  | Director | 15-Apr-2002 | Current |
| Rajiv Krishnamurthy | Director | 06-Feb-2007 | Current |
| Sardar Singh | Director | 04-Dec-2006 | Current |
Financial Performance of Citadel Aurobindo Biotech.
Citadel Aurobindo Biotech Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 44.42% decrease. The company also saw a substantial fall in profitability, with a 9583.74% decrease in profit. The company's net worth dipped by a decrease of 0.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Citadel Aurobindo Biotech?
In 2019, Citadel Aurobindo Biotech had a public holding of 100.00%. The company had 3 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Citadel Fine Pharmaceuticals Private LimitedRajiv Krishnamurthy is a mutual person
Charges (Loans)
₹0
₹40.00 Cr
Charges Breakdown by Lending Institutions
- Uti Bank Limited : 30.00 Cr
- Standard Chartered Bank : 10.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jan 2003 | Uti Bank Limited | ₹30.00 Cr | Satisfied |
| 21 Oct 2002 | Standard Chartered Bank | ₹10.00 Cr | Satisfied |
How Many Employees Work at Citadel Aurobindo Biotech?
Unlock and access historical data on people associated with Citadel Aurobindo Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Citadel Aurobindo Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Citadel Aurobindo Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
